CARM

Carisma Therapeutics Inc

Oct 03 • 04:00PM ET

0.2609

-0.0091 -3.37 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ GILD ALLO FATE ADAP ATRA AFMD AUTL NTLA SGMO

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	40.44%	Shs Outstand	41.79M	Perf Week	-9.97%
Market Cap	10.90M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-2.79%	Shs Float	24.89M	Perf Month	-18.47%
Enterprise Value	10.60M	PEG	-	EPS next Q	-0.12	Inst Own	4.29%	Short Float	6.30%	Perf Quarter	-33.95%
Income	-49.38M	P/S	1.01	EPS this Y	52.74%	Inst Trans	-17.51%	Short Ratio	0.18	Perf Half Y	35.81%
Sales	10.77M	P/B	-	EPS next Y	24.64%	ROA	-153.46%	Short Interest	1.57M	Perf YTD	-37.70%
Book/sh	-1.10	P/C	5.45	EPS next 5Y	32.95%	ROE	-362.79%	52W High	1.27 -79.46%	Perf Year	-72.64%
Cash/sh	0.05	P/FCF	-	EPS past 3/5Y	-240.97% 42.71%	ROIC	-	52W Low	0.14 84.12%	Perf 3Y	-92.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-9.57% -	Gross Margin	69.35%	Volatility	10.28% 13.34%	Perf 5Y	-97.71%
Dividend TTM	-	EV/Sales	0.98	EPS Y/Y TTM	33.60%	Oper. Margin	-428.26%	ATR (14)	0.04	Perf 10Y	-98.87%
Dividend Ex-Date	Mar 08, 2023	Quick Ratio	0.48	Sales Y/Y TTM	-48.01%	Profit Margin	-458.60%	RSI (14)	43.16	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.48	EPS Q/Q	12.95%	SMA20	-16.58%	Beta	2.06	Target Price	1.00
Payout	-	Debt/Eq	-	Sales Q/Q	-100.00%	SMA50	-13.61%	Rel Volume	0.15	Prev Close	0.27
Employees	46	LT Debt/Eq	-	Earnings	Aug 07	SMA200	-25.32%	Avg Volume	8.53M	Price	0.26
IPO	Feb 06, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	-155.56% -100.00%	Trades		Volume	1,304,287	Change	-3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Downgrade	Robert W. Baird	Outperform → Neutral	$10 → $1
Dec-10-24	Downgrade	BTIG Research	Buy → Neutral
Apr-11-24	Initiated	BTIG Research	Buy	$6
Oct-03-23	Initiated	CapitalOne	Overweight	$10
Jul-06-23	Initiated	Evercore ISI	Outperform	$12
May-31-23	Upgrade	Jefferies	Hold → Buy	$0.60 → $7
May-24-23	Initiated	H.C. Wainwright	Buy	$10
Apr-14-23	Initiated	Robert W. Baird	Outperform	$10

Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +104.65%
Jun-24-25 01:07PM	Carisma Therapeutics, OrthoCellix enter definitive merger agreement (TipRanks) -5.17%
Jun-23-25 07:30AM	Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire)
Mar-31-25 04:30PM	Carisma Therapeutics Provides Corporate Updates (PR Newswire) -6.06% -25.65%
Mar-26-25 08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
05:15PM	Loading…
Mar-19-25 05:15PM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-19-25 07:30AM	Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (PR Newswire)
Feb-05-25 07:30AM	Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire) +15.95%
Dec-09-24 08:30AM	Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline (PR Newswire)
Nov-27-24 07:30AM	Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-17-24 07:30AM	Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024 (PR Newswire)
Nov-08-24 07:30AM	Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma (PR Newswire)
Nov-07-24 07:30AM	Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire) -7.21%
Nov-05-24 09:05AM	Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 (PR Newswire)
Oct-30-24 04:30PM	Carisma Therapeutics Announces Changes to its Board of Directors (PR Newswire)
09:05AM	Loading…
Oct-04-24 09:05AM	Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 (PR Newswire)
Sep-10-24 07:30AM	Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases (PR Newswire)
Sep-03-24 07:30AM	Carisma Therapeutics to Present at Upcoming Conferences (PR Newswire) -6.54%
Aug-13-24 12:00PM	CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.79%
Aug-08-24 09:00AM	Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.63%
07:30AM	Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Aug-06-24 07:30AM	Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 (PR Newswire)
07:30AM	Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board (PR Newswire)
Jul-01-24 07:30AM	Carisma Therapeutics Announces Changes to its Board of Directors (PR Newswire) +9.87%
Jun-28-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +18.75%
Jun-27-24 04:30PM	Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna (PR Newswire)
Jun-26-24 06:53AM	Carisma Therapeutics solid tumour therapy obtains FDA Fast Track status (Pharmaceutical Technology) +6.09%
Jun-25-24 07:30AM	Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum (PR Newswire)
07:30AM	Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors (PR Newswire)
Jun-13-24 04:30PM	Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders (PR Newswire)
07:30AM	Loading…
May-30-24 07:30AM	Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-16-24 07:30AM	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte (PR Newswire)
May-09-24 01:54PM	CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:35AM	Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
May-08-24 07:30AM	Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 (PR Newswire)
May-06-24 07:30AM	Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference (PR Newswire)
May-02-24 10:01AM	Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
07:30AM	Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer (PR Newswire)
Apr-24-24 05:05PM	Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (PR Newswire)
Apr-22-24 04:35PM	Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (PR Newswire) +14.72% -9.09%
Apr-04-24 09:55AM	Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-03-24 07:00AM	Carisma Therapeutics to Present at Upcoming Conferences (PR Newswire)
Apr-01-24 01:53PM	CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.93%
08:35AM	Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
07:00AM	Carisma Therapeutics Announces Changes to its Board of Directors (PR Newswire)
Mar-21-24 05:00PM	Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-28-24 07:30AM	Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference (PR Newswire)
Dec-21-23 07:00AM	Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 07:00AM	First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration (PR Newswire)
Nov-28-23 07:00AM	Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte (PR Newswire)
Nov-22-23 07:30AM	Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference (PR Newswire) +5.74%
Nov-09-23 07:30AM	Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) -11.24%
Oct-31-23 09:25AM	Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC (PR Newswire)
Oct-25-23 09:11AM	Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023 (PR Newswire)
Oct-12-23 02:52PM	3 Top Under-$5 Stocks for Strong Gains and Positive Outlook (InvestorPlace) -19.51%
Sep-05-23 08:30AM	Carisma Therapeutics to Present at Upcoming Investor Conferences (PR Newswire) -14.33%
Sep-01-23 08:30AM	Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit (PR Newswire) -10.26%
Aug-24-23 08:30AM	Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 (PR Newswire)
Aug-23-23 09:55AM	Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know (Zacks)
Aug-13-23 08:07AM	Carisma Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-10-23 07:30AM	Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) +6.08%
Jul-19-23 06:34AM	Public companies own 19% of Carisma Therapeutics, Inc. (NASDAQ:CARM) shares but retail investors control 43% of the company (Simply Wall St.)
Jun-28-23 08:30AM	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors (PR Newswire)
Jun-26-23 08:30AM	Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes (PR Newswire) -5.24%
Jun-14-23 08:30AM	Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources (PR Newswire)
Jun-08-23 01:11PM	Carisma Therapeutics (NASDAQ:CARM) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-05-23 07:30AM	Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023 (PR Newswire)
May-30-23 04:30PM	Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023 (PR Newswire) +13.63%
May-11-23 07:30AM	Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (PR Newswire)
May-08-23 04:30PM	Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference (PR Newswire) +9.57% +8.07%
May-05-23 04:30PM	Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023 (PR Newswire) +8.63%
Apr-14-23 12:51PM	Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting (PR Newswire) +14.84%
Apr-06-23 04:30PM	Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023 (PR Newswire)
Apr-04-23 08:30AM	Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights (PR Newswire)
Mar-20-23 02:04PM	Carisma Therapeutics CEO Steven Kelly talks reverse merger, growth plans (American City Business Journals) -5.77%

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klichinsky Michael	Chief Scientific Officer	Oct 02 '25	Sale	0.25	200,000	50,860	119,347	Oct 03 05:25 PM
Klichinsky Michael	Chief Scientific Officer	Oct 01 '25	Sale	0.26	165,000	42,405	319,347	Oct 03 05:25 PM
Klichinsky Michael	Chief Scientific Officer	Oct 03 '25	Sale	0.26	119,347	31,078	0	Oct 03 05:25 PM
MICHAEL KLICHINSKY	Officer	Sep 30 '25	Proposed Sale	0.28	484,347	134,164		Sep 30 06:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CARM

Carisma Therapeutics Inc

Upgrade your FINVIZ experience